Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the safety and efficacy of laquinimod in treating relapsing-remitting multiple sclerosis (RRMS).
Methods: An extensive electronic search was conducted across PubMed, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov to identify suitable studies. Risk of bias was assessed using Cochrane's Risk of Bias tool. Statistical analysis was performed using RevMan 5.4.1.
Results: The meta-analysis of four randomized controlled trials including 3665 patients found that laquinimod significantly reduced the annualized relapse rate compared with placebo (mean difference = -0.08, 95% confidence interval [CI] = -0.12, -0.04, = 0%). For disability progression confirmed at 3 months, laquinimod provided a significant advantage over placebo (hazard ratio [HR] = 0.75, 95% CI = 0.59, 0.96, = 25%), whereas no benefit was achieved at 6 months (HR = 0.69, 95% CI = 0.45, 1.06, = 66%). Laquinimod was also significantly better than placebo in maintaining a relapse-free status (risk ratio [RR] = 1.14 95% CI = 1.06, 1.22, = 10%). Laquinimod had a comparable safety profile as placebo (RR = 1.06, 95% CI = 0.81, 1.39, = 33%).
Conclusions: These findings support the efficacy of laquinimod in managing RRMS but necessitate careful monitoring during treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806468 | PMC |
| http://dx.doi.org/10.1177/03000605241311437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mobility impairment and fall concern predict wayfinding ability in persons with multiple sclerosis.
Mult Scler Relat Disord
September 2025
Department of Psychology, Wayne State University, Detroit, MI, 48202, USA; Institute of Gerontology, Wayne State University, Detroit, MI, 48202, USA; Translational Neuroscience Program, Wayne State University, Detroit, MI, 48201, USA. Electronic address:
The ability to navigate through one's environment is crucial for maintaining independence in daily life and depends on complex cognitive and motor functions that are vulnerable to decline in persons with Multiple Sclerosis (MS). While previous research suggests a role for mobility in the physical act of navigation, it remains unclear to what extent mobility impairment and perceptions of mobility constraints may modify wayfinding and the recall of environment details in support of successful navigation. Therefore, this study examined the relations among clinical mobility function, concern about falling, and recall of environment details in a clinical sample of MS.
View Article and Find Full Text PDFEffects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
J Neurol
September 2025
College of Physical Education, China West Normal University, Nanchong, China.
Objective: This study aimed to evaluate the effects of various physical therapy interventions on fatigue and quality of life in patients with multiple sclerosis (MS) using a network meta-analysis of randomized controlled trials (RCTs).
Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Cochrane databases through April 1, 2025. Eligible RCTs compared different exercise interventions in MS patients, focusing on fatigue and quality of life outcomes.
Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification.
Front Immunol
September 2025
Neuroimmunology and Neuroinflammation Group, Biomedical Research Institute of Málaga-IBIMA Plataforma Bionand, Hospital Regional Universitario de Málaga, Málaga, Spain.
Background: Despite progress in serum biomarker research, reliable tools for early diagnosis and patient stratification in multiple sclerosis (MS) remain limited. This study uses proteomic profiling in untreated MS patients to identify early disease-associated biomarkers.
Methods: We conducted an unbiased proteomic screen to capture broad serum protein expression profiles in a well-characterized discovery sample: 7 relapsing remitting MS (RRMS), 7 secondary progressive MS (SPMS), 4 with primary progressive MS (PPMS) alongside 6 healthy controls (HC).
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK.
J Neurol Neurosurg Psychiatry
September 2025
Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
Background: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used as a one-off disease-modifying therapy for aggressive forms of multiple sclerosis (MS). We report real-world effectiveness of AHSCT for MS in the UK.
Methods: This retrospective open-label study included patients with (pw)MS treated with AHSCT between 2002 and 2023 in 14 UK centres.
Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?
Mult Scler J Exp Transl Clin
September 2025
Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Background: In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.
Objectives: To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.
Methods: In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks.